# Celldex Therapeutics, Inc. (CLDX) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Celldex Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/CLDX/mda/fy2025/): filed 2026-02-25; accession 0001104659-26-019652 (https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm); latest 10-K
- [FY 2024 MD&A](/company/CLDX/mda/fy2024/): filed 2025-02-27; accession 0001410578-25-000216 (https://www.sec.gov/Archives/edgar/data/744218/000141057825000216/cldx-20241231x10k.htm)
- [FY 2023 MD&A](/company/CLDX/mda/fy2023/): filed 2024-02-26; accession 0001410578-24-000076 (https://www.sec.gov/Archives/edgar/data/744218/000141057824000076/cldx-20231231x10k.htm)
- [FY 2022 MD&A](/company/CLDX/mda/fy2022/): filed 2023-02-28; accession 0001104659-23-026701 (https://www.sec.gov/Archives/edgar/data/744218/000110465923026701/cldx-20221231x10k.htm)
- [FY 2021 MD&A](/company/CLDX/mda/fy2021/): filed 2022-02-28; accession 0001104659-22-028070 (https://www.sec.gov/Archives/edgar/data/744218/000110465922028070/cldx-20211231x10k.htm)

Back to /company/CLDX/